{"analyses":[{"groupDescription":"Week 1 -24","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.5479","statisticalMethod":"Cochran-Mantel-Haenszel"},{"groupDescription":"Week 1 - 48","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.2980","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.70","upperLimit":"84.30","value":"50.0"},{"groupId":"OG001","lowerLimit":"4.33","upperLimit":"77.72","value":"33.3"}]}],"title":"Week 1 Through Week 24"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"24.49","upperLimit":"91.48","value":"62.5"},{"groupId":"OG001","lowerLimit":"4.33","upperLimit":"77.72","value":"33.3"}]}],"title":"Week 1 Through Week 48"}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"Percentage of participants who achieved a hematologic improvement platelet response (HI-P) was defined as the percentage of participants meeting the HI-P criteria per the IWG sustained over any consecutive 56-day (8-week) period (Week 1 to Week 24 and Week 1 to Week 48) during the treatment period. HI - P reponse was defined as:\n\n* Absolute increase of ≥ 30 X 10\\^9/L in platelets for participants starting with \\> 20 X 10\\^9/L platelets\n* Increase in platelets from \\< 20 X 10\\^9/L to \\> 20 X 10\\^9/L and by at least 100%","dispersionType":"95% Confidence Interval","groups":[{"description":"Luspatercept 1.0 mg/Kg SC on Day 1 of each 21-day treatment cycle","id":"OG000","title":"Luspatercept"},{"description":"Placebo (Volume equivalent to experimental arm) SC on Day 1 of each 21-day treatment cycle","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"All treated participants with available measurements","reportingStatus":"POSTED","timeFrame":"Week 1 through Week 24 or Week 1 Through Week 48 of study treatment","title":"Percentage of Participants Who Achieved a Hematologic Improvement in Platelet Response (HI-P) Over Any Consecutive 56-day Period","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}